GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

Teos' Belrestotug shows efficacy in trials, backed by a strong cash runway. Learn why ITOS stock might thrive with strategic ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab (brand name Jemperli) that has so far shown a 100 percent clinical ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...

Spatial analysis of the immune microenvironment and identification of phenotypes of prognostic significance in penile squamous cell carcinoma (PSCC). World-wide oligometastatic prostate cancer (omPC) ...

Lurie Cancer Center initiates trial combining LIXTE's LB-100 and GSK's Dostarlimab for ovarian clear cell cancer treatment. LIXTE Biotechnology Holdings, Inc. has announced that the Robert H.

Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab --PASADENA, ...

A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for six months. The trial conducted at Memorial Sloan Kettering Cancer Center ...

First up GSK, which got a green light for its PF-1 inhibitor Jemperli (dostarlimab) in combination with chemotherapy as a first-line treatment for all adult patients with primary advanced or ...

“We are pleased to be participating in this important clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s Dostarlimab will enhance the effectiveness of immunotherapy in the ...